This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kriengkauykiat, J.
Right arrow Articles by Wong-Beringer, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kriengkauykiat, J.
Right arrow Articles by Wong-Beringer, A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2005, p. 565-570, Vol. 49, No. 2
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.2.565-570.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Use of an Efflux Pump Inhibitor To Determine the Prevalence of Efflux Pump-Mediated Fluoroquinolone Resistance and Multidrug Resistance in Pseudomonas aeruginosa

Jane Kriengkauykiat,1 Edith Porter,2 Olga Lomovskaya,3 and Annie Wong-Beringer1,4*

School of Pharmacy University of Southern California,1 Department of Biological Sciences, California State University, Los Angeles,2 Mpex Pharmaceuticals, San Diego,2 Department of Pharmacy, Huntington Hospital, Pasadena, California2

Received 30 July 2004/ Returned for modification 3 October 2004/ Accepted 7 October 2004

Fluoroquinolone-resistance in Pseudomonas aeruginosa may be due to efflux pump overexpression (EPO) and/or target mutations. EPO can result in multidrug resistance (MDR) due to broad substrate specificity of the pumps. MC-04,124, an efflux pump inhibitor (EPI) shown to significantly potentiate activity of levofloxacin in P. aeruginosa, was used to examine the prevalence of EPO in clinical isolates. MICs were determined for ciprofloxacin, levofloxacin, moxifloxacin, and gatifloxacin with or without EPI and for other antipseudomonal agents by using broth microdilution against P. aeruginosa isolates from adults (n = 119) and children (n = 24). The prevalence of the EPO phenotype (≥8-fold MIC decrease when tested with EPI) was compared among subgroups with different resistance profiles. The EPO phenotype was more prevalent among levofloxacin-resistant than levofloxacin-sensitive strains (61%, 48/79 versus 9%, 6/64). EPO was present in 60% of fluoroquinolone-resistant strains without cross-resistance, while it was present at variable frequencies among strains with cross-resistance to other agents: piperacillin-tazobactam (86%), ceftazidime (76%), cefepime (65%), imipenem (56%), gentamicin (55%), tobramycin (48%), and amikacin (27%). The magnitude of MIC decrease with an EPI paralleled the frequency of which the EPO phenotype was observed in different subgroups. EPI reduced the levofloxacin MIC by as much as 16-fold in eight strains for which MICs were 128 µg/ml. Efflux-mediated resistance appears to contribute significantly to fluoroquinolone resistance and MDR in P. aeruginosa. Our data support the fact that increased fluoroquinolone usage can negatively impact susceptibility of P. aeruginosa to multiple classes of antipseudomonal agents.

* Corresponding author. Mailing address: University of Southern California, School of Pharmacy, 1985 Zonal Ave., Los Angeles, CA 90089. Phone: (323) 442-1356. Fax: (626) 628-3024. E-mail: anniew{at}usc.edu.

Antimicrobial Agents and Chemotherapy, February 2005, p. 565-570, Vol. 49, No. 2
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.2.565-570.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Nguyen, L. H., Hsu, D. I., Ganapathy, V., Shriner, K., Wong-Beringer, A. (2008). Reducing empirical use of fluoroquinolones for Pseudomonas aeruginosa infections improves outcome. J Antimicrob Chemother 61: 714-720 [Abstract] [Full Text]  
  • Robertson, G. T., Doyle, T. B., Du, Q., Duncan, L., Mdluli, K. E., Lynch, A. S. (2007). A Novel Indole Compound That Inhibits Pseudomonas aeruginosa Growth by Targeting MreB Is a Substrate for MexAB-OprM. J. Bacteriol. 189: 6870-6881 [Abstract] [Full Text]  
  • Rouveix, B. (2007). Clinical implications of multiple drug resistance efflux pumps of pathogenic bacteria. J Antimicrob Chemother 59: 1208-1209 [Abstract] [Full Text]  
  • Mahamoud, A., Chevalier, J., Alibert-Franco, S., Kern, W. V., Pages, J.-M. (2007). Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy. J Antimicrob Chemother 59: 1223-1229 [Abstract] [Full Text]  
  • Mesaros, N., Glupczynski, Y., Avrain, L., Caceres, N. E., Tulkens, P. M., Van Bambeke, F. (2007). A combined phenotypic and genotypic method for the detection of Mex efflux pumps in Pseudomonas aeruginosa. J Antimicrob Chemother 59: 378-386 [Abstract] [Full Text]  
  • Piddock, L. J. V. (2006). Clinically Relevant Chromosomally Encoded Multidrug Resistance Efflux Pumps in Bacteria. Clin. Microbiol. Rev. 19: 382-402 [Abstract] [Full Text]  
  • Poole, K. (2005). Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 56: 20-51 [Abstract] [Full Text]  
  • Hsu, D. I., Okamoto, M. P., Murthy, R., Wong-Beringer, A. (2005). Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes. J Antimicrob Chemother 55: 535-541 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»